AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00466843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Description: ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
Study NCT00466843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
Study NCT03566888 — intervention group
Intervention type: DEVICE
Intervention: Blood pressure assessment
Description: Validation of an automated blood pressure device
Study NCT02746146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic use of a prognostic score
Description: The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
Study NCT03173313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular permissive hypothermia as an adjunct to PCI
Description: Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
Study NCT05898685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
Study NCT05898685 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intermittent normoxia
Description: The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
Study NCT03046758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A combination of fosfomycin, metronidazole and GM-CSF i.p.
Description: All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
Study NCT00753571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cistanche Total Glycosides
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2
Study NCT00753571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cistanche Total Glycosides
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2
Study NCT01065597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonconvulsive electrotherapy
Description: An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
Study NCT02579837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos 200Tx
Description: non-mydriatic ultra-widefield (UWF) retinal imaging device
Study NCT02579837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss Cirrus
Description: optical coherence tomographer (OCT)
Study NCT00769210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg tablet
Study NCT01689519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib supplied as tablets
Study NCT01689519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib supplied as tablets
Study NCT01689519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib supplied as tablets
Study NCT03082430 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous PRP.
Description: one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
Study NCT01021527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C
Description: single dose administration of exenatide 10ug by subcutaneous injection
Study NCT00734175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H6N1 Teal HK 97/AA ca recombinant vaccine
Description: Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
Study NCT00183638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based tailored prevention messages
Description: Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
Study NCT02985372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
Study NCT02985372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01631773 — intervention group
Intervention type: GENETIC
Intervention: microRNA
Description: Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
Study NCT03725137 — intervention group
Intervention type: OTHER
Intervention: Analysis of T-lymphocytes
Description: Analysis of T-lymphocytes regarding the development of cognitive function after stroke
Study NCT02272660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium
Description: The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
Study NCT02272660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
Study NCT03389620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
Study NCT03389620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
Study NCT01164930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 8-week ACT group
Study NCT00183638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored messages
Description: The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
Study NCT03692949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: One dose administered (IV)
Study NCT03692949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT03692949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03692949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3451838
Description: One dose administered SC
Study NCT03285191 — intervention group
Intervention type: OTHER
Intervention: Numerical rating scale
Description: Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
Study NCT03285191 — intervention group
Intervention type: OTHER
Intervention: Real-time data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
Study NCT00755378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: Oral
Study NCT00755378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01937819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART arm
Description: The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
Study NCT02369120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
Study NCT02369120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal care by GP
Description: Patients will follow GP advice including NSAID medication if needed
Study NCT01245439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
Study NCT01409512 — intervention group
Intervention type: PROCEDURE
Intervention: ECG recording
Description: At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
Study NCT00591838 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Study NCT03673943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTATATE
Description: Detection of somatostatin positive lesions in NET
Study NCT03522519 — intervention group
Intervention type: BEHAVIORAL
Intervention: Real world performance of physical activity and arm use
Description: Patients will be assessed by using movement sensors and standard clinical assessments
Study NCT02770196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-CSA plus Nutrition Education
Description: Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
Study NCT02932358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Family Visitation Model (FFVM)
Description: Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
Study NCT02932358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Family Visitation Model (RFVM)
Description: Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
Study NCT01080599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Study NCT03045900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shaded bulk-fill resin composite
Description: Dental bulk-fill resin composite with shades A1, A2, A3
Study NCT03045900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shaded bulk-fill resin composite
Description: Dental bulk-fill resin composite with shades A1, A2, A3
Study NCT03413319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: Solution for infusion
Study NCT02508844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx®
Description: probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
Study NCT02508844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
Study NCT00560014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and canola oil
Description: Canola oil 1 tablespoon BID Arginine 9.0grams BID
Study NCT00560014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega and Arginine
Description: Arginine 9.0 grams BID Coromega dose based on weight
Study NCT04806256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System
Description: This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
Study NCT04806256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine intervention
Description: The routine intervention without CDSS is also the clinically common intervention at present.
Study NCT04593719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiment
Description: The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
Study NCT02727764 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
Study NCT03489317 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study NCT00423410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPC2407 (crinobulin)
Description: IV infusion 1 to 4 hours
Study NCT01515306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab (IMC-1121B)
Description: ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
Study NCT01109758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg
Study NCT01515306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
Study NCT00878917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2 % eye drops solution
Description: 1 drop into eye(s) three times a day for the duration of each treatment phase
Study NCT00335504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oligofructose-enriched inulin
Description: Given orally
Study NCT00335504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally
Study NCT00335504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00335504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally
Study NCT00335504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03489317 — intervention group
Intervention type: BEHAVIORAL
Intervention: lifestyle modification
Description: Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
Study NCT00335504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01021527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: graded glucose infusion
Description: A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
Study NCT01533935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium + olodaterol
Study NCT01533935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol
Description: Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
Study NCT01533935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + Olodaterol
Description: tiotropium 5 mcg + olodaterol 5 mcg once daily
Study NCT01533935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: tiotropium
Study NCT01533935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: Olodaterol 5 mcg once daily
Study NCT01533935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT01533935 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT04887844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Study NCT04887844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Study NCT01533935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT04887844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical therapy
Description: The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
Study NCT00261833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor
Description: 60 mg/kg body weight/week intravenous
Study NCT00261833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized preparation: 60 mg/kg body weight/week intravenous
Study NCT00633685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
Study NCT00633685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
Study NCT00103194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT00103194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03440437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS118
Description: Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
Study NCT03440437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
Study NCT02916030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vit D
Description: It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types